BioSpace News Archive

Labcorp, (NYSE: LH), a leading global life sciences company, announced today that Dr. Deborah Ann Sesok-Pizzini has been appointed Chief Medical Officer of Labcorp Diagnostics, following the retirement of Dr. Dot Adcock in April 2021.

Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating AD109 as a treatment for mild to moderate OSA.

Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz® in prevention and regression of type 1 diabetes.

Calyx, the eClinical and regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that its Medical Imaging and other eClinical solutions supported half of the oncology treatments approved by the FDA as Breakthrough Therapies in the past two years.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH)

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat at the B. Riley Oncology Institutional Investor Conference on Wednesday, January 20, 2021

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced its preliminary unaudited fourth quarter and full year 2020 revenues.

Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement,

Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma will acquire Minerva’s royalty interest in seltorexant for an upfront payment of $60 million and up to $95 million in additional milestone payments

CytomX Therapeutics, Inc. announced that on January 15, 2021, the Company granted two new employees options to purchase a total of 98,000 shares of the Company’s common stock at an exercise price per share equal to $7.93, which was the closing trading price on January 15, 2021, the date of the grant.